CorMedix Inc (CRMD)

[proffetti]

Forget the handle it's a parabolic move!

[proffetti]

Uh Oh! Cup and Handle Forming!

[proffetti]

We are on our way! up over 21% now

[tone3]

I found the article, thanks. 50 if all the other applications are approved

[proffetti]

Truist Securities initiates at Buy

Looking good foke!!

initiated at $20 a share.

[tone3]

Did I miss some new news

[proffetti]

$CRMD $16.44 Million in sales last Qtr.

That's a lot of product being used in Europe. The FDA should have no problem perusing this material and analyzing data. Next Qtr sales should dramatically increase as the new improved treatment is becoming well known. Once the FDA see's what's happening in Europe, approval should come rather quickly. Maybe this year.

[timberwolf7]

First, no need to worry about defending management with me. I didn't start riding this one heavily until it was down around 20-25 cents/sh... And as far as managements actions go? If I decide to stick around with an awareness of what they are doing, then its my 'responsibility' for my decision to do so.

Anyways, share price got the hit, but finally saw a 'buy' signal develop last week (forget the day I posted about it on the IV board). At the time, I picked up around 4000 shares at $4.14, promptly sold the Sept $4 calls for a 'net' gain of 64 cents/sh if I lose the shares at $4 on Septs OE day. (this buy was purely for the gains off the calls). And as that day approaches, I will look at what I paid for the calls, what it will cost to buy them back to close them out, and what I can sell another round for (most likely the $5s if I keep the shares).

And again, if I lose the shares, I am ok with the 16% one month gain...

Good luck...

[Lazerking40]

Not really surprised. Being a long time holder, it was pretty obvious a raise of some kind was coming. Sure they had cash on hand to get to Q2 2021 or whatever it was they said on their last call, but they all say that and you can't run the bank account to zero. Timing of the offering is somewhat unknown, but I think relatively soon and is definitely up for debate regarding what timeline is best. Do it after FDA approval and kill momentum putting shorts in the driver's seat, or right before FDA approval, take the 20%-25% hit to 5 or even 4.75, allow the shorts to load up, then announce FDA approval, get your bounce with the added bonus of a short squeeze. And maybe drive it to 7.5 or 8.... maybe higher if a squeeze does happen? I don't have a clue what they are thinking, but at least this isn't an Elliot sweetheart deal or a double warrant laden crap deal from what I can see. This does feel a little different than past raises and I for one am hopeful.....not bullish enough to recommend a buy, but bullish enough to hold and possibly buy more........And no, I am not an apologist for this company or management, just trying to understand leaving emotion on the sidelines. Good luck!

[timberwolf7]

well, with around 25 Million shares available for trading, and what looks like a 'go it alone' stance from management, they want to sell 10 million shares to raise $50 Million to get things going?? I don't like the hit to the 'top line share price', but if they make it to a market cap of $1 Billion,

I will take a share price of $28 with 35 Million shares outstanding vs $40 with 25 Million...

still a pretty nice return... especially if it helps them get to $28/sh...

[desarcmo]

CorMedix Announces Proposed Public Offering of Common Stock


BERKELEY HEIGHTS, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD) (the "Company"), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it plans to offer shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the size or terms of the proposed offering.

The Company plans to use the net proceeds for general corporate purposes, including obtaining regulatory approval and commercialization of Defencath(TM) in the U.S., research and development, and working capital and capital expenditures.

After hours has not had a favorable response, probably because of dilution concerns.

[whytestocks]

News: $CRMD CorMedix Inc. Reports Submission of Defencath(TM) New Drug Application

BERKELEY HEIGHTS, N.J., July 08, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that all of the ...

Read the whole news CRMD - CorMedix Inc. Reports Submission of Defencath(TM) New Drug Application

[desarcmo]

Moving along slowly. 60 days before NDA submission review complete. Then if given priority review another 6 months before approval. Nothing happening fast in the FDA review process.

BERKELEY HEIGHTS, N.J., July 08, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that all of the modules for the Defencath(TM) New Drug Application (NDA) have been submitted to the Food and Drug Administration (FDA). Defencath is being developed as a catheter lock solution with an initial indication for use of preventing catheter-related bloodstream infections (CRBSIs) in patients with end-stage renal disease who are receiving hemodialysis via a central venous catheter. The NDA was granted rolling submission and review by FDA as announced previously, and there has been ongoing dialogue with FDA as it reviews the submitted modules. The NDA contained data from the Company's Phase 3 trial, LOCK-IT-100, in patients undergoing hemodialysis for end-stage renal disease, which showed a 71% reduction in CRBSIs relative to the heparin control arm (p=0.0006) with a good safety profile.

The Company requested priority review of the NDA, based on the Fast Track and Qualified Infectious Disease Product Designations granted by FDA to Defencath. The FDA has 60 days to review the submission for completeness to make a filing decision and grant a priority or standard review. FDA will have a goal of a 6 month review period for priority review, compared to 10 months for a standard review.

https://content.seleritycorp.com/hosted2/assets/www/aFAIEVexU3HfOCIj6ORQ1WFxLSTBnqvkQ14RdHnFhJ0ath

[KC01905]

The lord giveth and the lord taketh away lol. What a bath today was all around.

[desarcmo]

Alive and well. Into second half of 2020 and waiting for the New Drug Approval (NDA) from the FDA, according to their February press release. Have not heard anything to the contrary and the pps has been rising so I consider that a good sign that all in on track. I really don't understand why there is not more interest in this stock. Granted they are low key and not a PR machine but looks like a solid company. Time will tell. Should be more action coming.

[KC01905]

This thing is still alive?!? Hadn't checked since this whole s%#t storm started.

[desarcmo]

This was reported back in February. Maybe NDA approval is moving along. We have just begun the second half of 2020.

CORMEDIX INC. ANNOUNCES FDA GRANT OF ROLLING REVIEW OF NEUTROLIN® NEW DRUG APPLICATION

Berkeley Heights, NJ — February 3, 2020 — CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and Drug Administration has granted the request for a rolling review of the New Drug Application (NDA) for Neutrolin® for the prevention of catheter-related blood stream infections (CRBSIs) in hemodialysis patients.

A rolling submission of the NDA is designed to expedite the review process for products being developed to address an unmet medical need. CorMedix remains on schedule for a potential NDA approval during the second half of 2020.

http://www.cormedix.com/cormedix-inc-announces-fda-grant-rolling-review-neutrolin-new-drug-application/

[tone3]

Maybe Something good coming our way

[thumper1]

whats the brew haha up 52 pennies

[desarcmo]

Updated April investor presentation. No big new news but looks like we are getting closer. Still saying FDA approval in 2H2020. Only probable big news between now and end of 2020 would be a new partnership or finance deal. Going to have to come up with dollars to go into production. Be patient.

http://www.cormedix.com/wp-content/uploads/2020/04/Corporate-Presentation-April-2020-2.pdf

[tone3]

Coming back from the hills. Good evaluation of CRMD!

[desarcmo]

People are running for the doors because of the upcoming dilution to raise funds. Don't see any way around that but the payoff still has the potential to be enormous once sales and production are on line. They have enough cash to last into early next year. Lot of things can happen between now and then. Partnership or buyout most likely scenarios, especially with PPS dropping like a rock. Buyout worst scenario for shareholders. May get some cash back but no need for anyone to offer a sweet deal to CRMD. A partnership will still offer the opportunity to enjoy the future cash income and PPS will eventually rise. This is still a crap shoot even though FDA approval appears to be likely.

[proffetti]

Dilute at will, while there's still sucker buyers out there.
Time to dilute and blame it on the market. Fast track my ass.

[rawsteel]

Yes but look what happened to Job after holding on to his integrity. He ended up having twice as much as he lost

[KC01905]

The lord giveth and the lord taketh away with this pig.

[rawsteel]

CorMedix Gets FDA Rolling Review of NDA for Neutrolin >CRMD

CorMedix Inc. (CRMD) said Monday the U.S. Food and Drug Administration has granted a request for a rolling review of the new drug application for Neutrolin for the prevention of catheter-related blood stream infections in hemodialysis patients.
The biopharmaceutical company said Neutrolin has received fast track designation from FDA and the company confirmed with the FDA in a pre-NDA meeting that it was eligible to request a rolling review.
CorMedix said it remains on schedule for a potential NDA approval during the second half of 2020.
CorMedix shares rose 5% to $6.66 in premarket trading.

[desarcmo]

Updated January 2020 investors presentation on CRMD website. Not a lot of new data but significant updates. All the big events scheduled 2nd half 2020. Will have to wait for that. I suspect that before then there could be announcements regarding fund raising or potential partnerships. At some point they will probably need more money. How this is handled will have a significant impact on short term share price. Still think long term looks very good.

[KC01905]

This thing will forever keep you on the edge of your seat.

[saturn_five]

Quick correction to B. Riley price target:
I see PT set at a more reasonable/conservative (?) $15.00
CRMD is rated "Buy"
Analyst: D'Silva ( at B. Riley FBR )
Source: Dow Jones Newswire
Maybe too optimistic, but I'm guessing a future buyout is still a possibility ?
I'm holding some Lucky $7's into 2020.
GLTA

[thumper1]

i'll take 8 by days end lol. in all seriousness, fwiw..fidelity is still showing the pr.

best to you and all.


--Analyst Actions: B. Riley Initiates Coverage on CorMedix With Buy Rating, $48 Price Target
BY MT Newswires
— 7:34 AM ET 12/18/2019

[KC01905]

How about just 8 by days end lol. I heard the 48 was off and was more like 15. Either way Marry Christmas to all next year for sure.

[thumper1]

looking strong again, i will take rileys rec, of $48.00

best to all

[ClayTrader]

* * $CRMD Video Chart 12-18-2019 * *

Link to Video - click here to watch the technical chart video

[thumper1]

B.Riley really likes CRMD...best to all longs

--Analyst Actions: B. Riley Initiates Coverage on CorMedix With Buy Rating, $48 Price Target

[desarcmo]

CorMedix (NYSEMKT:CRMD) initiated with Buy rating and $15 (129% upside) price target at B. Riley FBR. Shares up 4% premarket.

[tmeier]

Time to load it!! Hit low 5 's but where it's at now is near a low. Should see upside towards 10 or 11 at least. Has held up well most of the year.

[Rapture2020]

Chilling. Waiting on FDA’s AGRX decision.

Haven’t forgotten about CRMD. It’s back on my to-do list Q1 2020, LOL.

[janeyH]

hey , been quiet, what up?

[KC01905]

This thing couldn't have stayed down this week lol. Unbelievable. Never would have predicted what a buying opportunity we had. Unreal.

[Rapture2020]

Ha. This is one of those times I love being wrong. Not sure what’s going on but it’s good green and I know good people have been holding for awhile.


Congrats.

[desarcmo]

Have not heard any news today to justify this. Again, my speculation is that something is in the works. They will need some cash to get through the end of this and product on market. Maybe looking at a partnership or buyout, or some other creative cash raise. This run is just a prelude to when some big favorable tangible news comes out, even more when sales begin and money in the bank.

[KC01905]

Is Christmas coming early this year or is this just a fluke thing?!?

[desarcmo]

Moving up on decent volume. My guess is people think something in the works like potential partnership or buyout. Would be logical. No big catalyst expected till mid-late next year. Some kind of speculation is driving it up.

[Rapture2020]

No opinion. I usually take a month or so doing diligence before my next jump.

With respect to AGRX, binary event hopefully before Saturday. I think it’s a Go but there is always a risk, fyi.

Good luck out there.

[B52T38]

Thanks, Rapture! I'll check them out, too. Do you have an opinion on CTSO? I've been invested with them for 10 years, maybe more, I lose track. Been a long wait, but I'm still very optimisitic.

[Rapture2020]

I sold all CRMD and placed it into AGRX during August & September. Not sure what comes next.

Good luck.

[B52T38]

Thanks, Janey, I'll check them out! I was following your posts, too, back in the winter, maybe CRMD's year will be 2020 (same for CTSO, my primary investment).

[janeyH]

Not pumping, just sharing, you will want to listen to the SNWV conference call on Friday morning.

- in a huge market, diabetes, no one is getting any skinnier
– FDA approved
- generating revenue
- have billing code for reimbursements for doctors to make money
– Just signed a sales channel agreement With a 50 person salesforce that’s already in diabetes care



Check it out

[B52T38]

Hello, Rapture, I had a stake in CRMD for about 6 months, from last fall to about March of 2019. I'm out now, and just read your post about maybe the second half of 2020 being a possible time to get back in. Question: Between now and then, are you aware of any other possibly promising opportunities to stake an investment? You've always struck me as someone with foresight and knowledge, so that's why I ask. Thanks!

[Rapture2020]

I don’t think so. If FDA approval happens, it will be the 2nd half of 2020. There are no near term catalysts so this thing is just going to drift lower, IMO.

I will revisit 2nd Q 2020.